Warhound Raises $200 Million at a Reported $1.2 Billion to Clone Gene-Edited Military Dogs It Has Not Yet Bred

Warhound, a startup built by Colossal Biosciences chief executive Ben Lamm and Anduril founder Palmer Luckey, emerged from stealth on Oct. 23 with $200 million to clone and gene-edit working dogs for the U.S. military. TechCrunch reported a $1.2 billion valuation. The dogs it plans to sell have not been born.

What Warhound has raised and from whom

TechCrunch lists Sequoia, 8VC, Corner Ventures and In-Q-Tel among the investors. In-Q-Tel is the venture firm backed by the CIA and other U.S. intelligence agencies. TechCrunch does not name a lead investor, and Engadget, which also covered the launch, gives no valuation and no investor list at all.

The $1.2 billion figure therefore rests on one outlet. Warhound has no revenue to set it against, so the usual check, a multiple of sales, is unavailable. The nearest comparable by shape is another science-heavy company priced before it sells anything: Warp Sciences raised $215 million at $865 million this week.

Item	What the sources state
Round size	$200 million (TechCrunch, Engadget)
Valuation	$1.2 billion (TechCrunch only)
Lead investor	Not named by TechCrunch
Dogs born so far	None; first litters expected early 2027
Price per dog	Undetermined

Who owns what: Colossal, Anduril and David Spirk

Colossal holds equity in Warhound and licenses its technology to it, according to TechCrunch. Engadget adds that Lamm sits on the board and that David Spirk, formerly of Palantir, is chief executive.

Luckey is a partner but owns no equity, Lamm told TechCrunch. Anduril will supply protective vests, goggles and the software that ties handlers to their dogs. Viagen, another Colossal-owned company, will do the cloning. Several of the pieces Warhound needs are therefore supplied by related parties.

The market claim: 80 percent of dogs come from Europe

Warhound says more than 80 percent of U.S. military working dogs come from Europe and that fewer than half of them are fit for service, per TechCrunch. Lamm pointed to poor eyesight, cancer and hip dysplasia as reasons dogs fail training.

The company started from Belgian Malinois and German Shepherd lines and stored their cell lines in a biobank. It plans to edit genes to add performance traits and remove health risks, then clone the result. Pricing is not set. The named targets are the Department of Defense, military service groups, police forces and first responders.

What scientists say about cloning and editing at this scale

Scientific American spoke to outside researchers who were less certain. Lisa Moses, a veterinarian and bioethicist at Harvard University, said that cloning is inefficient and "requires a lot of dogs" to produce one puppy, and that the process can endanger surrogate mothers.

Ben Novak, chief scientist at Revive and Restore, said some traits arise from "hundreds or thousands of mutations across genes," which makes them hard to find and edit. Robert Lanza, a former chief scientific officer at the Astellas Institute for Regenerative Medicine, considers the goals achievable but expects many failures and defects.

TechCrunch found no independent review of the gene-editing work beyond the American Humane Society, which is helping certify the training program and may take retired dogs into its reunification program.

What to watch: early 2027 litters and the first buyer

The first batch is being cloned and incubated, with births expected in early 2027, and Lamm hopes the dogs reach service within two years. Until a litter exists and a government buyer signs, the round is a bet on a pipeline. The next concrete test is the first birth announcement, and a named customer would be the first revenue signal.

The defence angle is not unique to dogs. A DARPA test of an active-control space reactor is another example of government money flowing to unproven hardware this month.